Bridgeway Capital Management’s Matinas BioPharma MTNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-35
Closed -$4.2K – 1298
2024
Q2
$4.2K Hold
35
– – ﹤0.01% 1263
2024
Q1
$7.18K Sell
35
-94
-73% -$16.7K ﹤0.01% 1302
2023
Q4
$20.9K Hold
129
– – ﹤0.01% 1339
2023
Q3
$12.5K Sell
129
-133
-51% -$24.5K ﹤0.01% 1353
2023
Q2
$70.7K Sell
262
-476
-64% -$166K ﹤0.01% 1301
2023
Q1
$260K Sell
738
-133
-15% -$50.4K 0.01% 1050
2022
Q4
$327K Sell
871
-134
-13% -$66.9K 0.01% 972
2022
Q3
$479K Hold
1,005
– – 0.01% 907
2022
Q2
$595K Hold
1,005
– – 0.01% 842
2022
Q1
$606K Hold
1,005
– – 0.01% 891
2021
Q4
$761K Sell
1,005
-40
-4% -$32.1K 0.01% 853
2021
Q3
$1.02M Hold
1,045
– – 0.02% 819
2021
Q2
$607K Buy
1,045
+140
+15% +$90.3K 0.01% 1015
2021
Q1
$712K Sell
905
-524
-37% -$527K 0.01% 989
2020
Q4
$1.46M Buy
1,429
+302
+27% +$210K 0.03% 633
2020
Q3
$648K Buy
1,127
+174
+18% +$104K 0.01% 806
2020
Q2
$553K Buy
953
+500
+110% +$288K 0.01% 822
2020
Q1
$204K Hold
453
– – ﹤0.01% 1053
2019
Q4
$772K Hold
453
– – 0.01% 805
2019
Q3
$214K Hold
453
– – ﹤0.01% 1172
2019
Q2
$291K Hold
453
– – ﹤0.01% 1106
2019
Q1
$371K Buy
+453
New +$366K ﹤0.01% 1109
2018
Q2
– Sell
-252
Closed -$145K – 1440
2018
Q1
$145K Hold
252
– – ﹤0.01% 1296
2017
Q4
$219K Buy
252
+167
+196% +$161K ﹤0.01% 1268
2017
Q3
$84K Sell
85
-82
-49% -$82.1K ﹤0.01% 1354
2017
Q2
$211K Buy
+167
New +$336K ﹤0.01% 1279

Other funds holding MTNB

Bridgeway Capital Management's MTNB Position: Q3 2024 in Review

Bridgeway Capital Management sold out of Matinas BioPharma (MTNB) in Q3 2024, closing a stake of 35 shares — an estimated $4.2K sold.

Bridgeway Capital Management first reported a position in MTNB in Q2 2017 and held it in 26 quarters. The position peaked at $1.46M in Q4 2020. 18 funds tracked by Wall St. Rank hold MTNB as of Q3 2024.

  • Bridgeway Capital Management reported no remaining Matinas BioPharma position as of Q3 2024 after selling out during the quarter.
  • Bridgeway Capital Management sold 35 Matinas BioPharma shares in Q3 2024, an estimated $4.2K.
  • Bridgeway Capital Management first reported a position in Matinas BioPharma in Q2 2017 and held it in 26 quarters.
  • Bridgeway Capital Management's Matinas BioPharma position peaked at $1.46M in Q4 2020.
  • 18 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2024.

Based on Bridgeway Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.